(Q36750128)

16 August 2017

1 reference

title

Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report (English)

1 reference

16 August 2017

1 reference

Hom-Lay Wang

1 reference

16 August 2017

Daniel Weber

1 reference

16 August 2017

Laurie K McCauley

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Journal of Periodontology

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

584-594

1 reference

Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Development of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Alendronate disturbs vesicular trafficking in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Structure-activity relationships of various bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Extended safety profile of oral clodronate after long-term use in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Decimal point--osteoporosis therapy at the 10-year mark

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

21 January 2018

Once-monthly ibandronate

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Influence of estrogen status on endosseous implant osseointegration

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Reconstructing the skeleton with intermittent parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Metabolic effects of pamidronate in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

21 January 2018

1 reference

https://api.crossref.org/works/10.1902%2FJOP.2007.060239

Biosynthetic pathways from acetate to natural products

21 January 2018

1 reference

20 August 2023

https://opencitations.net/index/coci/api/v1/citations/10.1351/PAC196714010137

Identifiers

DOI

10.1902/JOP.2007.060239

1 reference

16 August 2017

1 reference